DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/reportinfo.asp?report_id=300120)
has announced the addition of "Espicom Business Intelligence's new
report: The Pharmaceutical Market: Vietnam" to their offering.
After years of poor regulation and IP protection, the Vietnamese
government has started to gain more control in the the administration
of drugs in the market, particularly in the area of price control. The
MoH has recently started a crackdown on firms that inflate the price
of drugs without prior permission from the Vietnam Drug Administration
(VDA), a requirement under the law that was passed in 2005. In 2007,
the MoH has come down hard on 13 companies that raised the price of
drugs without permission from the VDA, an agency under the MoH, and
issued a warning that such firms risk penalties such as fines, or
worse still, have their operating licences revoked.
IP laws are still poor, and the Vietnamese drug industry, which
has little R&D and makes mainly copycat drugs, supplies 40% of the
market. The government is keen to encourage the local industry to
supply around 60% of the market, therefore it is not in the best
interest of the government to pursue IP laws as aggressively as price
control mechanisms. That said, the country's accession in WTO in 2007
and accordance with the TRIPS agreement has seen the country make
strides in the formulation of IP laws and protection, but enforcement
remains a problem.
The opening of the economy since the doi moi reforms of the
mid-1980s has created a demand for Western drugs which cannot be met
by the local industry. Imports, therefore, comprise a significant
proportion of the market by value. European suppliers dominate, with
the French at the forefront, due to their long historical ties with
the region. US manufacturers have only been able to directly supply
Vietnam since the lifting of the US government trade boycott in 1994.
Key Topics:
- Executive Summary
- Pharmaceutical Market
- Key National Data Projections
- Geography
- Political Overview
- Economic Overview
- Population 8.Demographic Indicators
- Mortality
- Morbidity
- Organisation & Administration
- Health Expenditure
- Hospital Services
- Ambulatory Care
- Medical Personnel
- Regulatory Environment
- Distribution Channels
- Pharmaceutical Imports
- Domestic Production & Exports
- Directory
For more information visit
http://www.researchandmarkets.com/reportinfo.asp?report_id=300120
Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax: +353 1 4100 980
Copyright Business Wire 2008
